Search

Each record is a registered study, a systematic-review registration or a publication. A registered or ongoing study is not a finding, and animal or cell research does not show an effect in people. The same study can appear under more than one subject, so the number of records is not a count of independent studies. You can also search an exact DOI, PubMed ID, NCT or CRD number. How to read these records.

8 study records (showing up to 30 per record type)

• Registered trial NCT05623852 Not completed: Recruiting
  The Impact of Oligo-Fucoidan in Cancer Cachexia and Sarcopenia
  Condition or outcome area: Cachexia
  2022-01-30 · Subject: Fucoidan; Fucoidan-Ascophyllum nodosum · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT05616507 Not completed: Recruiting
  Oligo-Fucoidan Decrease Lung Radiation Damage
  Condition or outcome area: Radiation Toxicity
  2022-03-30 · Subject: Fucoidan; Fucoidan-Ascophyllum nodosum · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT05437887 Not completed: Recruiting
  Effects of Fucoidan on the Gut Microbiota in the Patients of Atopic Dermatitis
  Condition or outcome area: Atopic Dermatitis
  2022-10-04 · Subject: Fucoidan; Fucoidan-Ascophyllum nodosum · open the ingredient record · ClinicalTrials.gov
• Systematic review registration CRD42016034051 Registered protocol, no results here: Review Ongoing
  Effect of fucoidan on breast cancer: a systematic review
  Condition or outcome area: Breast cancer is cancer that develops from breast tissue. Signs of breast cancer may include a lump in the breast, a change in breast shape, dimpling of the skin, fluid coming from the nipple, or a red scaly patch of skin. In those with distant spread of the disease, there may be bone pain, swollen lymph nodes, shortness of breath, or yellow skin.
  2016-02-05 · Subject: Fucoidan; (2S,3S,4S,5S,6R)-4,5-Dihydroxy-2,6-dimethyltetrahydro-2H-pyran-3-yl hydrogen sulfate; Antiviral agent 51; 2165969-58-2; [(2S,3S,4S,5S,6R)-4,5-Dihydroxy-2,6-dimethyloxan-3-yl] hydrogen sulfate; Fucoidan - Alaria; Fucoidan - Ecklonia; Fucoidan - Durvillea; Fucoidan - Sargassum; Fucoidan - Cladosiphon · open the ingredient record
• Publication PMID 35200646 Research model: Cell Experiment
  Fucoidan Isolated from Sargassum confusum Suppresses Inflammatory Responses and Oxidative Stress in TNF-α/IFN-γ- Stimulated HaCaT Keratinocytes by Activating Nrf2/HO-1 Signaling Pathway
  Condition or outcome area: tumor
  Mar Drugs · 2022 · Subject: Hai Zao; 海藻; Seaweed; Sargassum · open the herb record · DOI 10.3390/md20020117
• Publication PMID 32604764 Research model: Cell Experiment
  Degradation of Sargassum crassifolium Fucoidan by Ascorbic Acid and Hydrogen Peroxide, and Compositional, Structural, and In Vitro Anti-Lung Cancer Analyses of the Degradation Products
  Condition or outcome area: lung cancer; lung carcinoma
  Mar Drugs · 2020 · Subject: Hai Zao; 海藻; Seaweed; Sargassum · open the herb record · DOI 10.3390/md18060334
• Publication PMID 33922488 Research model: Animal & Cell Experiment
  Fucoidan from Laminaria japonica Inhibits Expression of GLUT9 and URAT1 via PI3K/Akt, JNK and NF-κB Pathways in Uric Acid-Exposed HK-2 Cells
  Condition or outcome area: hyperuricemia
  Mar Drugs · 2021 · Subject: Hai Dai; 海带; Ellgrass; Laminaria Japonica · open the herb record · DOI 10.3390/md19050238
• Publication PMID 33708111 Research model: Animal & Cell Experiment
  Fucoidan Ameliorates Renal Injury-Related Calcium-Phosphorus Metabolic Disorder and Bone Abnormality in the CKD-MBD Model Rats by Targeting FGF23-Klotho Signaling Axis
  Condition or outcome area: chronic kidney disease; bone metabolic disorder; renal tubulointerstitial damage; Klotho deficiency; calcium-phosphorus metabolic disorder; bone disorder; renal dysfunction; bone abnormality; bone lesion
  Front Pharmacol · 2021 · Subject: Hai Dai; 海带; Ellgrass; Laminaria Japonica · open the herb record · DOI 10.3389/fphar.2020.586725